BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2011-12-07

AUTHORS

Michael S. Niederman, Jean Chastre, Kevin Corkery, James B. Fink, Charles-Edouard Luyt, Miguel Sánchez García

ABSTRACT

PurposeTo conduct a multicenter, randomized, placebo-controlled, double-blind, phase II study of BAY41-6551 (NCT01004445), an investigational drug–device combination of amikacin, formulated for inhalation, and a proprietary Pulmonary Drug Delivery System, for the treatment of Gram-negative pneumonia in mechanically ventilated patients.MethodsSixty-nine mechanically ventilated patients with Gram-negative pneumonia, a clinical pulmonary infection score ≥6, at risk for multidrug-resistant organisms, were randomized to BAY41-6551 400 mg every 12 h (q12h), 400 mg every 24 h (q24h) with aerosol placebo, or placebo q12h for 7–14 days, plus standard intravenous antibiotics. The combined primary endpoint was a tracheal aspirate amikacin maximum concentration ≥6,400 μg/mL (25 × 256 μg/mL reference minimum inhibitory concentration) and a ratio of area under the aspirate concentration–time curve (0–24 h) to minimum inhibitory concentration ≥100 on day 1.ResultsThe primary endpoint was achieved in 50% (6/12) and 16.7% (3/18) of patients in the q12h and q24h groups, respectively. Clinical cure rates, in the 48 patients getting ≥7 days of therapy, were 93.8% (15/16), 75.0% (12/16), and 87.5% (14/16) in the q12h, q24h, and placebo groups, respectively (p = 0.467). By the end of aerosol therapy, the mean number of antibiotics per patient per day was 0.9 in the q12h, 1.3 in the q24h, and 1.9 in the placebo groups, respectively (p = 0.02 for difference between groups). BAY41-6551 was well tolerated and attributed to two adverse events in one patient (mild bronchospasm).ConclusionsBAY41-6551 400 mg q12h warrants further clinical evaluation. More... »

PAGES

263-271

Journal

TITLE

Intensive Care Medicine

ISSUE

2

VOLUME

38

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00134-011-2420-0

DOI

http://dx.doi.org/10.1007/s00134-011-2420-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1023392555

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22147112


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aerosols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Amikacin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Bacterial Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Body Fluids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gram-Negative Bacterial Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Microbial Sensitivity Tests", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pneumonia, Bacterial", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pneumonia, Ventilator-Associated", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Respiration, Artificial", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Trachea", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Winthrop-University Hospital, 222 Station Plaza N., Suite 509, 11501, Mineola, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.281603.e", 
          "name": [
            "Department of Medicine, Winthrop-University Hospital, 222 Station Plaza N., Suite 509, 11501, Mineola, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Niederman", 
        "givenName": "Michael S.", 
        "id": "sg:person.01305416464.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01305416464.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Piti\u00e9-Salp\u00e9tri\u00e8re, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.411439.a", 
          "name": [
            "H\u00f4pital Piti\u00e9-Salp\u00e9tri\u00e8re, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chastre", 
        "givenName": "Jean", 
        "id": "sg:person.0714077601.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0714077601.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis Pharmaceuticals Corporation (formerly Nektar Therapeutics), San Carlos, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Novartis Pharmaceuticals Corporation (formerly Nektar Therapeutics), San Carlos, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Corkery", 
        "givenName": "Kevin", 
        "id": "sg:person.0752144541.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752144541.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Aerogen Limited (formerly Nektar Therapeutics), Galway, Ireland", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Aerogen Limited (formerly Nektar Therapeutics), Galway, Ireland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fink", 
        "givenName": "James B.", 
        "id": "sg:person.0721371273.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0721371273.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Piti\u00e9-Salp\u00e9tri\u00e8re, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.411439.a", 
          "name": [
            "H\u00f4pital Piti\u00e9-Salp\u00e9tri\u00e8re, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Luyt", 
        "givenName": "Charles-Edouard", 
        "id": "sg:person.01310337776.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310337776.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Cl\u00ednico San Carlos, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411068.a", 
          "name": [
            "Hospital Cl\u00ednico San Carlos, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Garc\u00eda", 
        "givenName": "Miguel S\u00e1nchez", 
        "id": "sg:person.014757317051.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014757317051.56"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00134-010-1879-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046735722", 
          "https://doi.org/10.1007/s00134-010-1879-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/cc8206", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010862289", 
          "https://doi.org/10.1186/cc8206"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00134-009-1605-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033258941", 
          "https://doi.org/10.1007/s00134-009-1605-2"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-12-07", 
    "datePublishedReg": "2011-12-07", 
    "description": "PurposeTo conduct a multicenter, randomized, placebo-controlled, double-blind, phase II study of BAY41-6551 (NCT01004445), an investigational drug\u2013device combination of amikacin, formulated for inhalation, and a proprietary Pulmonary Drug Delivery System, for the treatment of Gram-negative pneumonia in mechanically ventilated patients.MethodsSixty-nine mechanically ventilated patients with Gram-negative pneumonia, a clinical pulmonary infection score \u22656, at risk for multidrug-resistant organisms, were randomized to BAY41-6551 400\u00a0mg every 12\u00a0h (q12h), 400\u00a0mg every 24\u00a0h (q24h) with aerosol placebo, or placebo q12h for 7\u201314\u00a0days, plus standard intravenous antibiotics. The combined primary endpoint was a tracheal aspirate amikacin maximum concentration \u22656,400\u00a0\u03bcg/mL (25\u00a0\u00d7\u00a0256\u00a0\u03bcg/mL reference minimum inhibitory concentration) and a ratio of area under the aspirate concentration\u2013time curve (0\u201324\u00a0h) to minimum inhibitory concentration \u2265100 on day 1.ResultsThe primary endpoint was achieved in 50% (6/12) and 16.7% (3/18) of patients in the q12h and q24h groups, respectively. Clinical cure rates, in the 48 patients getting \u22657\u00a0days of therapy, were 93.8% (15/16), 75.0% (12/16), and 87.5% (14/16) in the q12h, q24h, and placebo groups, respectively (p\u00a0=\u00a00.467). By the end of aerosol therapy, the mean number of antibiotics per patient per day was 0.9 in the q12h, 1.3 in the q24h, and 1.9 in the placebo groups, respectively (p\u00a0=\u00a00.02 for difference between groups). BAY41-6551 was well tolerated and attributed to two adverse events in one patient (mild bronchospasm).ConclusionsBAY41-6551 400\u00a0mg q12h warrants further clinical evaluation.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00134-011-2420-0", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1313639", 
        "issn": [
          "0342-4642", 
          "1432-1238"
        ], 
        "name": "Intensive Care Medicine", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "38"
      }
    ], 
    "keywords": [
      "Gram-negative pneumonia", 
      "placebo group", 
      "primary endpoint", 
      "Clinical Pulmonary Infection Score", 
      "standard intravenous antibiotics", 
      "phase II study", 
      "clinical cure rate", 
      "days of therapy", 
      "multidrug-resistant organisms", 
      "concentration-time curve", 
      "pulmonary drug delivery systems", 
      "drug-device combination", 
      "intravenous antibiotics", 
      "II study", 
      "adverse events", 
      "cure rate", 
      "minimum inhibitory concentration", 
      "clinical evaluation", 
      "amikacin concentrations", 
      "infection score", 
      "patients", 
      "q12h", 
      "BAY41", 
      "pneumonia", 
      "mean number", 
      "inhibitory concentration", 
      "q24h", 
      "placebo", 
      "ratio of area", 
      "therapy", 
      "endpoint", 
      "drug delivery systems", 
      "antibiotics", 
      "days", 
      "delivery system", 
      "group", 
      "multicenter", 
      "PurposeTo", 
      "amikacin", 
      "maximum concentration", 
      "inhalation", 
      "treatment", 
      "scores", 
      "risk", 
      "concentration", 
      "warrants", 
      "evaluation", 
      "study", 
      "rate", 
      "events", 
      "combination", 
      "number", 
      "ratio", 
      "end", 
      "curves", 
      "organisms", 
      "area", 
      "system", 
      "achieves"
    ], 
    "name": "BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia", 
    "pagination": "263-271", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1023392555"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00134-011-2420-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22147112"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00134-011-2420-0", 
      "https://app.dimensions.ai/details/publication/pub.1023392555"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:29", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_546.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00134-011-2420-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00134-011-2420-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00134-011-2420-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00134-011-2420-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00134-011-2420-0'


 

This table displays all metadata directly associated to this object as RDF triples.

239 TRIPLES      21 PREDICATES      102 URIs      91 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00134-011-2420-0 schema:about N01ab47f534f540318c23f19766111e65
2 N03cf1213234548dcb9dd38ec694720c6
3 N1d2a228034944e6299f9f1cb3a284036
4 N25c77e2bd291449f9f0443555cd04a6e
5 N26ed56803e884a8faa903e8fc299e53f
6 N367718b4d0ab486db272eaf3a0c0331d
7 N3b8b1fbe5d8e4ea991fecc7f20a94180
8 N4940aec738d0444587424df875957db6
9 N4c1bf28204a94ba48bcbf5ba9b7153a3
10 N67a51765ff2e4dbf8b623f5c9f53dac6
11 N831904fdc5e8455ea20986f167a53626
12 N8b836c84290d417a83a3ac0003eca079
13 N9b5fa801af5a4fbcbb76e79770dc4361
14 Naf0b6bd6dc1346e59992b60d7e32a0d9
15 Nee79271618d84ca0b8d9c9d927f432a1
16 anzsrc-for:11
17 anzsrc-for:1103
18 schema:author Nedb1847f0ba442d1ab09773915475658
19 schema:citation sg:pub.10.1007/s00134-009-1605-2
20 sg:pub.10.1007/s00134-010-1879-4
21 sg:pub.10.1186/cc8206
22 schema:datePublished 2011-12-07
23 schema:datePublishedReg 2011-12-07
24 schema:description PurposeTo conduct a multicenter, randomized, placebo-controlled, double-blind, phase II study of BAY41-6551 (NCT01004445), an investigational drug–device combination of amikacin, formulated for inhalation, and a proprietary Pulmonary Drug Delivery System, for the treatment of Gram-negative pneumonia in mechanically ventilated patients.MethodsSixty-nine mechanically ventilated patients with Gram-negative pneumonia, a clinical pulmonary infection score ≥6, at risk for multidrug-resistant organisms, were randomized to BAY41-6551 400 mg every 12 h (q12h), 400 mg every 24 h (q24h) with aerosol placebo, or placebo q12h for 7–14 days, plus standard intravenous antibiotics. The combined primary endpoint was a tracheal aspirate amikacin maximum concentration ≥6,400 μg/mL (25 × 256 μg/mL reference minimum inhibitory concentration) and a ratio of area under the aspirate concentration–time curve (0–24 h) to minimum inhibitory concentration ≥100 on day 1.ResultsThe primary endpoint was achieved in 50% (6/12) and 16.7% (3/18) of patients in the q12h and q24h groups, respectively. Clinical cure rates, in the 48 patients getting ≥7 days of therapy, were 93.8% (15/16), 75.0% (12/16), and 87.5% (14/16) in the q12h, q24h, and placebo groups, respectively (p = 0.467). By the end of aerosol therapy, the mean number of antibiotics per patient per day was 0.9 in the q12h, 1.3 in the q24h, and 1.9 in the placebo groups, respectively (p = 0.02 for difference between groups). BAY41-6551 was well tolerated and attributed to two adverse events in one patient (mild bronchospasm).ConclusionsBAY41-6551 400 mg q12h warrants further clinical evaluation.
25 schema:genre article
26 schema:isAccessibleForFree false
27 schema:isPartOf N5b81f2c007834f0ca89bace1615baed0
28 Nc106ed20097e496aa6b0d8019e1886a1
29 sg:journal.1313639
30 schema:keywords BAY41
31 Clinical Pulmonary Infection Score
32 Gram-negative pneumonia
33 II study
34 PurposeTo
35 achieves
36 adverse events
37 amikacin
38 amikacin concentrations
39 antibiotics
40 area
41 clinical cure rate
42 clinical evaluation
43 combination
44 concentration
45 concentration-time curve
46 cure rate
47 curves
48 days
49 days of therapy
50 delivery system
51 drug delivery systems
52 drug-device combination
53 end
54 endpoint
55 evaluation
56 events
57 group
58 infection score
59 inhalation
60 inhibitory concentration
61 intravenous antibiotics
62 maximum concentration
63 mean number
64 minimum inhibitory concentration
65 multicenter
66 multidrug-resistant organisms
67 number
68 organisms
69 patients
70 phase II study
71 placebo
72 placebo group
73 pneumonia
74 primary endpoint
75 pulmonary drug delivery systems
76 q12h
77 q24h
78 rate
79 ratio
80 ratio of area
81 risk
82 scores
83 standard intravenous antibiotics
84 study
85 system
86 therapy
87 treatment
88 warrants
89 schema:name BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia
90 schema:pagination 263-271
91 schema:productId N1d552ff727ee4ccf95f7f0c77240d35a
92 N4432b0b7bd644476bf6137ef56d7011e
93 N5bdf35022d1d4ac69183233e24d24cae
94 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023392555
95 https://doi.org/10.1007/s00134-011-2420-0
96 schema:sdDatePublished 2022-12-01T06:29
97 schema:sdLicense https://scigraph.springernature.com/explorer/license/
98 schema:sdPublisher N1dadbd2f9d484e1588fd9d5136b3c357
99 schema:url https://doi.org/10.1007/s00134-011-2420-0
100 sgo:license sg:explorer/license/
101 sgo:sdDataset articles
102 rdf:type schema:ScholarlyArticle
103 N01ab47f534f540318c23f19766111e65 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Gram-Negative Bacterial Infections
105 rdf:type schema:DefinedTerm
106 N03cf1213234548dcb9dd38ec694720c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Amikacin
108 rdf:type schema:DefinedTerm
109 N0f85c06dca6d49e0a043f2bedce0a7f9 rdf:first sg:person.0752144541.89
110 rdf:rest Nea432fc83f8d433d9a2e4570bf78cebe
111 N1d2a228034944e6299f9f1cb3a284036 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Anti-Bacterial Agents
113 rdf:type schema:DefinedTerm
114 N1d552ff727ee4ccf95f7f0c77240d35a schema:name dimensions_id
115 schema:value pub.1023392555
116 rdf:type schema:PropertyValue
117 N1dadbd2f9d484e1588fd9d5136b3c357 schema:name Springer Nature - SN SciGraph project
118 rdf:type schema:Organization
119 N25c77e2bd291449f9f0443555cd04a6e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Respiration, Artificial
121 rdf:type schema:DefinedTerm
122 N26ed56803e884a8faa903e8fc299e53f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Aerosols
124 rdf:type schema:DefinedTerm
125 N367718b4d0ab486db272eaf3a0c0331d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Pneumonia, Bacterial
127 rdf:type schema:DefinedTerm
128 N3b8b1fbe5d8e4ea991fecc7f20a94180 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Double-Blind Method
130 rdf:type schema:DefinedTerm
131 N4432b0b7bd644476bf6137ef56d7011e schema:name doi
132 schema:value 10.1007/s00134-011-2420-0
133 rdf:type schema:PropertyValue
134 N4940aec738d0444587424df875957db6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Male
136 rdf:type schema:DefinedTerm
137 N4c1bf28204a94ba48bcbf5ba9b7153a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Female
139 rdf:type schema:DefinedTerm
140 N52289ec761674446b47ccfc7f689464f rdf:first sg:person.0714077601.27
141 rdf:rest N0f85c06dca6d49e0a043f2bedce0a7f9
142 N5b81f2c007834f0ca89bace1615baed0 schema:volumeNumber 38
143 rdf:type schema:PublicationVolume
144 N5bdf35022d1d4ac69183233e24d24cae schema:name pubmed_id
145 schema:value 22147112
146 rdf:type schema:PropertyValue
147 N67a51765ff2e4dbf8b623f5c9f53dac6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Humans
149 rdf:type schema:DefinedTerm
150 N831904fdc5e8455ea20986f167a53626 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Middle Aged
152 rdf:type schema:DefinedTerm
153 N8b836c84290d417a83a3ac0003eca079 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Body Fluids
155 rdf:type schema:DefinedTerm
156 N97e249553ae54c38b959ab6cd63868fb rdf:first sg:person.014757317051.56
157 rdf:rest rdf:nil
158 N9b5fa801af5a4fbcbb76e79770dc4361 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Trachea
160 rdf:type schema:DefinedTerm
161 Naf0b6bd6dc1346e59992b60d7e32a0d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Pneumonia, Ventilator-Associated
163 rdf:type schema:DefinedTerm
164 Nc106ed20097e496aa6b0d8019e1886a1 schema:issueNumber 2
165 rdf:type schema:PublicationIssue
166 Nd2ced068bcc9470a8eeef72bc3f5d9af rdf:first sg:person.01310337776.72
167 rdf:rest N97e249553ae54c38b959ab6cd63868fb
168 Nea432fc83f8d433d9a2e4570bf78cebe rdf:first sg:person.0721371273.52
169 rdf:rest Nd2ced068bcc9470a8eeef72bc3f5d9af
170 Nedb1847f0ba442d1ab09773915475658 rdf:first sg:person.01305416464.55
171 rdf:rest N52289ec761674446b47ccfc7f689464f
172 Nee79271618d84ca0b8d9c9d927f432a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Microbial Sensitivity Tests
174 rdf:type schema:DefinedTerm
175 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
176 schema:name Medical and Health Sciences
177 rdf:type schema:DefinedTerm
178 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
179 schema:name Clinical Sciences
180 rdf:type schema:DefinedTerm
181 sg:journal.1313639 schema:issn 0342-4642
182 1432-1238
183 schema:name Intensive Care Medicine
184 schema:publisher Springer Nature
185 rdf:type schema:Periodical
186 sg:person.01305416464.55 schema:affiliation grid-institutes:grid.281603.e
187 schema:familyName Niederman
188 schema:givenName Michael S.
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01305416464.55
190 rdf:type schema:Person
191 sg:person.01310337776.72 schema:affiliation grid-institutes:grid.411439.a
192 schema:familyName Luyt
193 schema:givenName Charles-Edouard
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310337776.72
195 rdf:type schema:Person
196 sg:person.014757317051.56 schema:affiliation grid-institutes:grid.411068.a
197 schema:familyName García
198 schema:givenName Miguel Sánchez
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014757317051.56
200 rdf:type schema:Person
201 sg:person.0714077601.27 schema:affiliation grid-institutes:grid.411439.a
202 schema:familyName Chastre
203 schema:givenName Jean
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0714077601.27
205 rdf:type schema:Person
206 sg:person.0721371273.52 schema:affiliation grid-institutes:None
207 schema:familyName Fink
208 schema:givenName James B.
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0721371273.52
210 rdf:type schema:Person
211 sg:person.0752144541.89 schema:affiliation grid-institutes:grid.418424.f
212 schema:familyName Corkery
213 schema:givenName Kevin
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752144541.89
215 rdf:type schema:Person
216 sg:pub.10.1007/s00134-009-1605-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033258941
217 https://doi.org/10.1007/s00134-009-1605-2
218 rdf:type schema:CreativeWork
219 sg:pub.10.1007/s00134-010-1879-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046735722
220 https://doi.org/10.1007/s00134-010-1879-4
221 rdf:type schema:CreativeWork
222 sg:pub.10.1186/cc8206 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010862289
223 https://doi.org/10.1186/cc8206
224 rdf:type schema:CreativeWork
225 grid-institutes:None schema:alternateName Aerogen Limited (formerly Nektar Therapeutics), Galway, Ireland
226 schema:name Aerogen Limited (formerly Nektar Therapeutics), Galway, Ireland
227 rdf:type schema:Organization
228 grid-institutes:grid.281603.e schema:alternateName Department of Medicine, Winthrop-University Hospital, 222 Station Plaza N., Suite 509, 11501, Mineola, NY, USA
229 schema:name Department of Medicine, Winthrop-University Hospital, 222 Station Plaza N., Suite 509, 11501, Mineola, NY, USA
230 rdf:type schema:Organization
231 grid-institutes:grid.411068.a schema:alternateName Hospital Clínico San Carlos, Madrid, Spain
232 schema:name Hospital Clínico San Carlos, Madrid, Spain
233 rdf:type schema:Organization
234 grid-institutes:grid.411439.a schema:alternateName Hôpital Pitié-Salpétrière, Paris, France
235 schema:name Hôpital Pitié-Salpétrière, Paris, France
236 rdf:type schema:Organization
237 grid-institutes:grid.418424.f schema:alternateName Novartis Pharmaceuticals Corporation (formerly Nektar Therapeutics), San Carlos, CA, USA
238 schema:name Novartis Pharmaceuticals Corporation (formerly Nektar Therapeutics), San Carlos, CA, USA
239 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...